CA2975043C - Composition for a wound dressing - Google Patents
Composition for a wound dressing Download PDFInfo
- Publication number
- CA2975043C CA2975043C CA2975043A CA2975043A CA2975043C CA 2975043 C CA2975043 C CA 2975043C CA 2975043 A CA2975043 A CA 2975043A CA 2975043 A CA2975043 A CA 2975043A CA 2975043 C CA2975043 C CA 2975043C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- acid
- component
- chitosan
- triprotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 134
- 229920001661 Chitosan Polymers 0.000 claims abstract description 126
- 150000007521 triprotic acids Chemical class 0.000 claims abstract description 117
- 229920002101 Chitin Polymers 0.000 claims abstract description 43
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 239000008247 solid mixture Substances 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 138
- 206010052428 Wound Diseases 0.000 claims description 45
- 208000027418 Wounds and injury Diseases 0.000 claims description 45
- -1 flakes Substances 0.000 claims description 35
- 239000012876 carrier material Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 12
- 239000004599 antimicrobial Substances 0.000 claims description 11
- 239000004753 textile Substances 0.000 claims description 9
- 229920000297 Rayon Polymers 0.000 claims description 8
- 230000000845 anti-microbial effect Effects 0.000 claims description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 4
- 229920002413 Polyhexanide Polymers 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229940108928 copper Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960001774 octenidine Drugs 0.000 claims description 2
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 239000004627 regenerated cellulose Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000032770 biofilm formation Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 description 72
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 68
- 239000000835 fiber Substances 0.000 description 37
- 239000004310 lactic acid Substances 0.000 description 34
- 235000014655 lactic acid Nutrition 0.000 description 34
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 32
- 239000002953 phosphate buffered saline Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- 239000000463 material Substances 0.000 description 30
- 244000005700 microbiome Species 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 150000007518 monoprotic acids Chemical class 0.000 description 20
- 239000007195 tryptone soya broth Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 13
- 238000003556 assay Methods 0.000 description 11
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 6
- 230000006196 deacetylation Effects 0.000 description 6
- 238000003381 deacetylation reaction Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000006150 trypticase soy agar Substances 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920005830 Polyurethane Foam Polymers 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001804 debridement Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 4
- 239000011496 polyurethane foam Substances 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 229920006264 polyurethane film Polymers 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000012085 chronic inflammatory response Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002407 reforming Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000344861 Staphylococcus aureus subsp. aureus NCTC 8325 Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1501330.3 | 2015-01-27 | ||
| GBGB1501330.3A GB201501330D0 (en) | 2015-01-27 | 2015-01-27 | Composition for a wound dressing |
| PCT/GB2016/050178 WO2016120620A1 (en) | 2015-01-27 | 2016-01-27 | Composition for a wound dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2975043A1 CA2975043A1 (en) | 2016-08-04 |
| CA2975043C true CA2975043C (en) | 2023-05-23 |
Family
ID=52673990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2975043A Active CA2975043C (en) | 2015-01-27 | 2016-01-27 | Composition for a wound dressing |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180008742A1 (enExample) |
| EP (1) | EP3250243B8 (enExample) |
| JP (1) | JP6974176B2 (enExample) |
| KR (1) | KR102608156B1 (enExample) |
| CN (2) | CN118846182A (enExample) |
| AU (1) | AU2016210991B2 (enExample) |
| BR (1) | BR112017016093B1 (enExample) |
| CA (1) | CA2975043C (enExample) |
| DK (1) | DK3250243T3 (enExample) |
| ES (1) | ES2944592T3 (enExample) |
| FI (1) | FI3250243T3 (enExample) |
| GB (2) | GB201501330D0 (enExample) |
| PL (1) | PL3250243T4 (enExample) |
| PT (1) | PT3250243T (enExample) |
| SA (1) | SA517381996B1 (enExample) |
| WO (1) | WO2016120620A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0811530B1 (pt) | 2007-05-14 | 2019-01-02 | Research Foundation Of State Univ Of New York | composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície |
| GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
| GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| EP4162968A1 (en) | 2010-12-08 | 2023-04-12 | ConvaTec Technologies Inc. | System for removing exudates from a wound site |
| CN103347561B (zh) | 2010-12-08 | 2016-09-07 | 康沃特克科技公司 | 用于评估伤口分泌液的集成系统 |
| JP6151186B2 (ja) | 2010-12-08 | 2017-06-21 | コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ | 創傷滲出液システム付属装置 |
| GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
| GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
| CN105008611A (zh) | 2012-12-20 | 2015-10-28 | 康沃特克科技公司 | 化学改性的纤维素纤维的处理 |
| GB2543544A (en) | 2015-10-21 | 2017-04-26 | Brightwake Ltd | Wound dressing |
| CA3019436A1 (en) | 2016-03-30 | 2017-10-05 | Qualizyme Diagnostics Gmbh & Co Kg | Detecting microbial infection in wounds |
| CN109310528B (zh) | 2016-03-30 | 2021-07-20 | 康沃特克科技公司 | 检测伤口中的微生物感染 |
| GB201608099D0 (en) | 2016-05-09 | 2016-06-22 | Convatec Technologies Inc | Negative pressure wound dressing |
| TW201805034A (zh) | 2016-07-08 | 2018-02-16 | 美商康瓦鐵克科技股份有限公司 | 彈性的負壓系統 |
| US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
| PL3481360T3 (pl) | 2016-07-08 | 2022-05-02 | Convatec Technologies Inc. | Wykrywanie przepływu płynu |
| WO2019040729A1 (en) * | 2017-08-24 | 2019-02-28 | Kci Usa, Inc. | BIOMATERIAL AND METHODS OF MAKING AND USING THE BIOMATERIAL |
| TR201713929A2 (tr) | 2017-09-20 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Ki̇tosan ve alji̇natin hemostati̇k kompozi̇syonlari |
| US12161792B2 (en) | 2017-11-16 | 2024-12-10 | Convatec Limited | Fluid collection apparatus |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020131806A1 (en) * | 2018-12-21 | 2020-06-25 | Kci Licensing, Inc. | Wound dressings including pvp-citric acid copolymer |
| JP7511585B2 (ja) | 2019-06-03 | 2024-07-05 | コンバテック リミティド | 病原体を破壊して封じ込めるための方法およびデバイス |
| US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
| US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0968931A1 (en) * | 1998-07-02 | 2000-01-05 | The Procter & Gamble Company | A flexible package with easy-opening peel seal |
| ZA200309861B (en) * | 2001-06-14 | 2004-12-20 | Providence Health Sys Oregon | Wound dressing and method for controlling severe, life-threatening bleeding. |
| AU2002364491A1 (en) * | 2002-01-03 | 2003-07-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Edible compositions capable of removing oral biofilm |
| JP2003292501A (ja) * | 2002-04-01 | 2003-10-15 | Koyo Chemical Kk | キトサンスポンジおよびその製造方法 |
| CN1778397B (zh) * | 2004-11-26 | 2011-05-11 | 龚正烈 | 对烧烫伤皮肤有癒合效果的纳米壳聚糖溶胶及制造方法 |
| JP4976662B2 (ja) * | 2005-06-24 | 2012-07-18 | 大日精化工業株式会社 | キトサン微粒子 |
| WO2007047425A1 (en) * | 2005-10-12 | 2007-04-26 | Cellular Bioengineering, Inc. | Resorbable cornea button |
| JP4866173B2 (ja) * | 2006-01-25 | 2012-02-01 | 大日精化工業株式会社 | ヒドロキシアルキル化キトサン溶液 |
| CN101081308A (zh) * | 2007-05-14 | 2007-12-05 | 罗晓浔 | 壳聚糖止血剂 |
| CL2008000156A1 (es) * | 2008-01-18 | 2008-08-01 | Igloo Zone Chile S A | Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel. |
| CN101239199A (zh) * | 2008-03-18 | 2008-08-13 | 施建基（SHI/JianJi） | 自粘型壳聚糖止血膜及其制备方法 |
| JP5936536B2 (ja) * | 2009-03-16 | 2016-06-22 | ユニバーシティー オブ メンフィス リサーチ ファウンデーション | 傷に剤を届けるための組成物および方法 |
| US8469538B2 (en) * | 2010-01-21 | 2013-06-25 | Polygroup Macau Limited (Bvi) | Inflatable decorative structure with a light system and a diffusing member |
| RU2468129C2 (ru) * | 2010-12-30 | 2012-11-27 | Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный университет им. Н.Г. Чернышевского" | Биополимерное волокно, состав формовочного раствора для его получения, способ приготовления формовочного раствора, полотно биомедицинского назначения, способ его модификации, биологическая повязка и способ лечения ран |
| KR101329261B1 (ko) * | 2012-05-16 | 2013-11-13 | (주)태봉 | 키토산을 이용한 기능성 부직포 및 그 제조방법 |
| GB201220076D0 (en) * | 2012-11-07 | 2012-12-19 | Medtrade Products Ltd | Wound care device |
| CN103848926B (zh) * | 2012-11-30 | 2016-03-02 | 江春平 | 一种羧化壳聚糖的制备方法和用途 |
| EP2941128B1 (en) * | 2012-12-20 | 2023-06-28 | Rajiv Bhushan | Antimicrobial compositions |
| EP3569262A1 (en) | 2013-03-14 | 2019-11-20 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
| GB201501334D0 (en) * | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
-
2015
- 2015-01-27 GB GBGB1501330.3A patent/GB201501330D0/en not_active Ceased
-
2016
- 2016-01-27 PL PL16707503.5T patent/PL3250243T4/pl unknown
- 2016-01-27 CN CN202410854968.4A patent/CN118846182A/zh active Pending
- 2016-01-27 US US15/546,643 patent/US20180008742A1/en not_active Abandoned
- 2016-01-27 AU AU2016210991A patent/AU2016210991B2/en active Active
- 2016-01-27 EP EP16707503.5A patent/EP3250243B8/en active Active
- 2016-01-27 JP JP2017557503A patent/JP6974176B2/ja active Active
- 2016-01-27 PT PT167075035T patent/PT3250243T/pt unknown
- 2016-01-27 ES ES16707503T patent/ES2944592T3/es active Active
- 2016-01-27 BR BR112017016093-5A patent/BR112017016093B1/pt active IP Right Grant
- 2016-01-27 CN CN201680012118.3A patent/CN107580506A/zh active Pending
- 2016-01-27 DK DK16707503.5T patent/DK3250243T3/da active
- 2016-01-27 WO PCT/GB2016/050178 patent/WO2016120620A1/en not_active Ceased
- 2016-01-27 CA CA2975043A patent/CA2975043C/en active Active
- 2016-01-27 KR KR1020177023028A patent/KR102608156B1/ko active Active
- 2016-01-27 GB GB1601531.5A patent/GB2537008B/en active Active
- 2016-01-27 FI FIEP16707503.5T patent/FI3250243T3/fi active
-
2017
- 2017-07-26 SA SA517381996A patent/SA517381996B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180008742A1 (en) | 2018-01-11 |
| FI3250243T3 (fi) | 2023-03-15 |
| DK3250243T3 (da) | 2023-02-20 |
| KR102608156B1 (ko) | 2023-11-29 |
| AU2016210991A1 (en) | 2017-08-17 |
| PT3250243T (pt) | 2023-02-22 |
| AU2016210991B2 (en) | 2020-03-12 |
| GB2537008A (en) | 2016-10-05 |
| CA2975043A1 (en) | 2016-08-04 |
| WO2016120620A1 (en) | 2016-08-04 |
| RU2017129870A3 (enExample) | 2019-08-19 |
| JP2018506402A (ja) | 2018-03-08 |
| EP3250243B8 (en) | 2022-12-21 |
| GB2537008B (en) | 2019-10-23 |
| JP6974176B2 (ja) | 2021-12-01 |
| ES2944592T3 (es) | 2023-06-22 |
| KR20170107011A (ko) | 2017-09-22 |
| SA517381996B1 (ar) | 2021-12-23 |
| EP3250243B1 (en) | 2022-11-16 |
| GB201601531D0 (en) | 2016-03-09 |
| BR112017016093B1 (pt) | 2021-05-11 |
| RU2017129870A (ru) | 2019-03-01 |
| BR112017016093A2 (pt) | 2018-03-27 |
| EP3250243A1 (en) | 2017-12-06 |
| PL3250243T3 (pl) | 2023-04-03 |
| CN118846182A (zh) | 2024-10-29 |
| PL3250243T4 (pl) | 2023-04-03 |
| GB201501330D0 (en) | 2015-03-11 |
| CN107580506A (zh) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10973691B2 (en) | Composition for a wound dressing | |
| CA2975043C (en) | Composition for a wound dressing | |
| AU2016210993B2 (en) | Composition for a wound dressing | |
| RU2842190C2 (ru) | Композиция для раневых повязок | |
| RU2838416C2 (ru) | Композиция для раневых повязок | |
| RU2775940C2 (ru) | Композиция для раневых повязок |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |
|
| EEER | Examination request |
Effective date: 20210126 |